Skip to main content

Table 1 The clinical features of hepatocellular carcinoma patients in model cohort and validation cohort

From: Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in patients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort

 

Model group (n = 348)

Validation cohort (n = 348)

P value

Death [n (%)]

130 (37.4)

123 (35.3)

0.582

Survival time (mean ± SD, month)

28.0 ± 23.7

26.6 ± 22.6

0.439

Age (mean ± SD, year)

59.5 ± 13.4

59.6 ± 13.4

0.569

Gender (male/female)

236/112

236/112

1.0

AJCC stage (IV/III/II/I/NA)

4/80/79/164/21

7/70/67/182/22

0.226

AJCC PT (T4/T3/T2/T1/NA)

14/74/87/171/2

10/71/75/192/0

0.163

AJCC PN (N3/N2/N1/N0/NA)

100/3/245/0

117/3/228/0

0.165

AJCC PM (MX/M1/M0/NA)

96/4/248/0

103/7/238/0

0.392

Radiation treatment adjuvant (yes/no/NA)

4/130/114

5/225/118

0.631

Pharmaceutical adjuvant (yes/no/NA)

15/215/118

12/213/123

0.592

Ablation embolization (yes/no/NA)

13/219/116

18/210/120

0.328

  1. Continuous variables were compared by using t-test or Mann–Whitney U test as appropriate; categorical variables were compared by using Chi-squared test or Fisher’s exact test as appropriate
  2. NA missing data, SD standard deviation, AJCC American Joint Committee on Cancer